Stanford researchers use CRISPR to edit sickle cell mutations, possibly laying the groundwork for a clinical trial, Reuters reports.
In Science this week: approach to uncover recent changes in allele frequencies, and more.
Utah's Dana Carroll, UC Berkeley's Jacob Corn, and their colleagues replaced the sickle cell disease mutation with the wild-type gene via HDR.
Researchers describe using a CRISPR approach to edit the sickle cell gene in vitro, the Los Angeles Times reports.
In PNAS this week: work toward a CRISPR/Cas9-based approach to treat beta-thalassemia or sickle cell disease, bacteriophages uncovered in human stool, and more.
In Nature this week: Exome Aggregation Consortium analysis of some 60,000 exomes, and more.
Scientists introduced an indel to a promoter region to mimic a benign, naturally-occurring mutation that activated fetal hemoglobin production.
Protective genetic mutations are providing a blueprint for companies wanting to treat sickle cell, Scientific American reports.
The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.
By editing a promoter of an enhancer of the mutated hemoglobin responsible for sickle cell disease, the researchers may have found a way to treat it.
Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.
The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.
The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.
In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.